ReviewExpert review of anti-infective therapy2023
Cytomegalovirus viremia and advanced HIV disease: is there an argument for anti-CMV treatment?
Review in Expert review of anti-infective therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 9 citations in OpenAlex.
- HIV-driven virome dysbiosis unveils distinct virome features and inter-viral correlations in blood and respiratory niches.Communications biology · 2026Article
- Small bowel perforation due to cytomegalovirus infection in a patient with HIVBiomedica : revista del Instituto Nacional de Salud · 2026Article
- Cytomegalovirus in HIV: A Modifiable Driver of Inflammation, Frailty, and Aging.Current HIV/AIDS reports · 2026Review
- Serological and Molecular Prevalence of HCMV, HCV, HBV andCurrent HIV research · 2026Article
- Valganciclovir for cytomegalovirus viraemia in advanced HIV disease: a phase 2b randomized placebo-controlled trial of valganciclovir for cytomegalovirus viraemia in adults and adolescents with advanced HIV disease.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2025Article
- Metagenomic next-generation sequencing for pathogen detection of pulmonary infections in persons living with HIV.AIDS research and therapy · 2025Article
- HIV Infection Complicated with Cytomegalovirus Colitis: A Case Report of 18FFDG PET/CT Imaging.Current medical imaging · 2025Article
- Proceedings of the Conference "CMV Vaccine Development-How Close Are We?" (27-28 September 2023).Vaccines · 2024Article
- Cytomegalovirus tracheobronchitis mimicking lung cancer progression in a patient with lung adenocarcinoma: A case report.Thoracic cancer · 2024Article
- Cryptococcal meningitis.Nature reviews. Disease primers · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionThe role of cytomegalovirus (CMV) infection as a co-factor in HIV disease has been a topic of considerable interest since the beginning of the HIV pandemic. CMV is believed to function both as a co-factor in the progression of HIV infection, and as a contributor to enhanced disease for other opportunistic infections. AREAS COVERED: In this special article, we review several recent studies that have enhanced our understanding of the role that CMV infection plays in the natural history of other HIV-related opportunistic infections. We review the clinical evidence that demonstrates how CMV viremia has emerged as an independent risk factor for the progression of infections such as those caused by EXPERT OPINION: Evidence suggests that active CMV replication, manifest as CMV viremia (DNAemia), may play a key role in driving progression of HIV-associated opportunistic infections. We propose that control of CMV replication, independent of the known benefit of HAART therapy on reducing CMV end-organ disease, could reduce the risk of disease and mortality attributable to opportunistic infections such as cryptococcosis and tuberculosis. This could be achieved by the targeted use of CMV antivirals. The advent of newer (and safer) orally bioavailable CMV antivirals has renewed interest in, and opportunities for, randomized controlled trials to evaluate CMV viremia as a modifiable risk factor in high-risk persons with HIV disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.